Chen-Hung Lee1, Ming-Jer Hsieh1, Shang-Hung Chang1, Kuo-Chun Hung1, Chao-Jan Wang2, Ming-Yi Hsu2, Jyuhn-Huarng Juang3, I-Chang Hsieh1, Ming-Shien Wen1, Shih-Jung Liu4,5. 1. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Medicine, Linkou, Taiwan. 2. Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou, Tao-Yuan, Taiwan. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital, Tao-Yuan, Taiwan. 4. Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, Taiwan. 5. Department of Orthopedic Surgery, Chang Gung Memorial Hospital-Linkou, Tao-Yuan 33305, Taiwan.
Abstract
BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated. RESEARCH DESIGN AND METHODS: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography. RESULTS: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group. CONCLUSION: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases.
BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated. RESEARCH DESIGN AND METHODS: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography. RESULTS: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group. CONCLUSION: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases.
Authors: Alaa J Hassiba; Mohamed E El Zowalaty; Gheyath K Nasrallah; Thomas J Webster; Adriaan S Luyt; Aboubakr M Abdullah; Ahmed A Elzatahry Journal: Nanomedicine (Lond) Date: 2016-01-08 Impact factor: 5.307
Authors: Sigmund Silber; Antonio Colombo; Adrian P Banning; Karl Hauptmann; Janusz Drzewiecki; Eberhard Grube; Dariusz Dudek; Donald S Baim Journal: Circulation Date: 2009-09-28 Impact factor: 29.690
Authors: Marie-Claude Drolet; Eric Plante; Bruno Battistini; Jacques Couet; Marie Arsenault Journal: Cardiovasc Ultrasound Date: 2004-07-21 Impact factor: 2.062
Authors: Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun Journal: Adv Drug Deliv Rev Date: 2021-01-09 Impact factor: 15.470
Authors: Annunziata Nusca; Michele Mattia Viscusi; Francesco Piccirillo; Aurelio De Filippis; Antonio Nenna; Cristiano Spadaccio; Francesco Nappi; Camilla Chello; Fabio Mangiacapra; Francesco Grigioni; Massimo Chello; Gian Paolo Ussia Journal: Life (Basel) Date: 2022-03-08